Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First Line Treatment With VeNEtoclaX and ibruTinib Induction Followed by Obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients Not in Complete Remission and/or With Detectable Bone Marrow Minimal Residual Disease (NEXT STEP Trial)

Next Previous
Trial Profile

First Line Treatment With VeNEtoclaX and ibruTinib Induction Followed by Obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients Not in Complete Remission and/or With Detectable Bone Marrow Minimal Residual Disease (NEXT STEP Trial)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 13 Dec 2022 Interim results (n=30) evaluating safety and efficacy of patients until the end of cycle 8, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 20 Aug 2021 Status changed from recruiting to active, no longer recruiting.
  • 05 Dec 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top